4.1 The manner of application
This section describes the manner of application specified in paragraph 4.2.6 and
sections 7.1 and 7.3 of Procedure (G9).
4.1.1 The proposal for Basic Approval and Final Approval should include the intended
minimum and maximum dosage and maximum allowable discharge concentrations of Active
Substances, if applicable.
4.1.2 The proposal should also include the manner of application of the Active Substance
or the Preparation by the BWMS to ensure the dosage and concentrations mentioned in
paragraph 4.1.1 above.
4.1.3 For Basic Approval submissions, the applicant should prepare all the information
on the manner of application after receiving the results on 'Readiness evaluation (refer
to paragraph 1.5 of Part 1 of the annex to the 2016 Guidelines (G8))' from the relevant
Administration (refer to paragraph 8.1.2.2 of Procedure (G9)). Furthermore, the
application dossier should include information on the major components, as identified in
paragraph 3.9 of the 2016 Guidelines (G8), in the proposed BWMS. This is understood to
mean that the neutralization process to ensure the MADC is not such a component, because
it does not directly affect the ability of the BWMS to meet the ballast water
performance standard described in regulation D-2 of the Convention.
4.1.4 The description of the manner of application should include a control scheme
showing that the Active Substance dose and the MADC can be maintained effectively in the
BWMS at all times, in particular at the beginning of discharge. An overdose against
stoichiometric demand is needed in this regard.
4.1.5 MADC should be ensured even under extreme conditions of SDLs (such as lower
temperature) (refer to paragraph 2.5.1 of Part 2 of the annex to the 2016 Guidelines
(G8)). Under extreme low temperatures an additional overdose of the neutralizer is
needed.
4.1.6 To verify the reliability and completion of the control scheme of the neutralizer
together with Active Substance monitoring, it is recommended that at Basic Approval
applicants should perform a simulation of discharge immediately after treatment (when
the maximum amount of neutralizer will be needed). The raw monitored data shown below
should be provided in the application:
-
.1 Active Substance concentration at, prior to and after the neutralization
process;
-
.2 calculated overdose ratio against the stoichiometric demand;
-
.3 dose of the neutralization; and
-
.4 measurement results on Active Substance and on the residual concentration of
the neutralizer discharged by using manual methods.
4.1.7 In relation to section 7 of Procedure (G9), the dossier should contain the
necessary data addressing the following items:
-
.1 the technical manual or instructions by the Administration, including the
product specification, process description, operational instructions, details of
the major components and materials used, technical installation specifications,
system limitations, and routine maintenance should be provided. The technical
manual should also clearly specify the dosage to be added to ballast water and the
maximum discharge concentration of the Active Substance therein;
-
.2 recommended methods and precautions concerning handling, use, storage, and
transport;
-
.3 procedures to be followed in case of fire, and the nature of reaction products,
combustion gases, etc.;
-
.4 measures to be taken in emergency situations;
-
.5 an indication of the possibility of destruction or decontamination following
emergency release in the marine environment;
-
.6 procedures for the management of wastes that may be generated during the
operation of the BWMS;
-
.7 the manner or procedure of reuse or recycling of Active Substances or
Preparations, if applicable;
-
.8 the possibility of neutralization;
-
.9 conditions for controlled discharge;
-
.10 minimum retention timefootnote of treated water on board before discharge (see
paragraph 5.2.7 of Procedure (G9));
-
.11 the amount of substance on board ship; and
-
.12 if an Active Substance is used that is convertible to TRO, the dose should be
expressed as mg/L as Cl2.
4.1.8 The discharge concentration of Active Substance should be continuously monitored
in an appropriate manner at all times. The monitoring point of Active Substance should
be positioned prior to the sampling facility, as specified in the 2016 Guidelines (G8).
If the sampling facility is placed prior to the monitoring point of the Active
Substance, the MADC may not yet have been reached, due to insufficient chemical reaction
time.
4.1.9 Appropriate risk management measures (e.g. for neutralization of the Active
Substance in case of emergency or if PEC/PNEC at discharge > 1) should be described.
These management measures are an integral part of the ballast water management system
and should be evaluated in the assessment.